brand logo

Am Fam Physician. 2021;103(7):442-443

This clinical content conforms to AAFP criteria for CME.

Author disclosure: No relevant financial affiliations.

Key Points for Practice

• The shorter STOP tool for evaluating OSA is easier to administer than the STOP-BANG criteria but equally sensitive.

• PAP is the most effective OSA treatment, although mandibular advancement devices are easier for patients to use.

• The Insomnia Severity Index and Athens Insomnia Scale are useful to grade insomnia before and after treatment.

• CBT is the most effective treatment for chronic insomnia, whereas sleep hygiene education alone is potentially harmful.

From the AFP Editors

Sleep disturbances are common and likely underdiagnosed. Obstructive sleep apnea (OSA) affects up to 38% of U.S. adults, especially men, postmenopausal women, and people with a higher body mass index. Insomnia symptoms affect up to 30% of U.S. adults, with up to 10% meeting criteria for chronic insomnia disorder. The U.S. Department of Veterans Affairs and Department of Defense (VA/DoD) approved a clinical practice guideline for the management of OSA and chronic insomnia disorder.

Diagnosis of OSA

Testing for sleep apnea should be considered based on clinical risk. The STOP and STOP-BANG criteria had the highest sensitivities for OSA screening, but using the shorter STOP tool (Table 1) is recommended because it is easier to administer. People with cardiovascular or cerebrovascular events, congestive heart failure, or long-term opioid use are considered high risk regardless of STOP score, although the evidence behind this recommendation is weak.

Snoring
Tiredness – fatigue or daytime sleepiness
Observed apnea episodes
Pressure – history of hypertension

In-laboratory polysomnography is the standard for diagnosing OSA. The diagnosis can also be made using home sleep apnea testing, with an unattended portable monitor. The home sleep apnea test can report the respiratory disturbance index, respiratory event index, or apnea-hypopnea index; 15 or more events per hour on any one index indicates OSA. Patients with a high risk of OSA and negative home sleep apnea test results should receive repeat testing, with home sleep apnea testing or polysomnography.

Treatment of OSA

For patients with OSA, positive airway pressure (PAP) for the entirety of the sleep period is the most studied and only beneficial treatment for severe disease. The effect of PAP on cardiovascular events is unproven. Because many patients struggle with adherence, educational, behavioral, and supportive interventions should be considered to improve use. Less than the recommended four hours per night of PAP use is still beneficial. Mandibular advancement devices are appropriate for mild to moderate OSA and improve adherence. Although PAP is better at reducing apneic and hypopneic episodes, use of a mandibular advancement device results in similar improvement in daytime sleepiness, cognitive function, vigilance, hypertension, and quality of life.

If standard therapy is ineffective, referral to a sleep specialist is warranted. Surgical referral may be helpful if nasal obstruction reduces PAP adherence, or in certain cases of severe OSA with poor PAP adherence where hypoglossal nerve stimulation therapy or maxillomandibular advancement surgery might be helpful. Interventions not recommended include isolated oxygen treatment for patients who cannot tolerate other therapies, as well as topical nasal steroids for the sole purpose of improving PAP adherence.

Assessment of Chronic Insomnia Disorder

Consider medical, substance-related, and psychiatric causes before diagnosing chronic insomnia disorder. Because of the variable symptoms of insomnia, using the Insomnia Severity Index or Athens Insomnia Scale may help grade symptom severity and monitor treatment effects. It is not necessary to repeat diagnostic testing when standard treatment is ineffective.

Treatment of Chronic Insomnia Disorder

Cognitive behavior therapy (CBT) for insomnia is the best treatment for chronic insomnia. CBT for insomnia includes sleep restriction therapy, stimulus control, sleep hygiene education, and relaxation therapy and counterarousal strategies. Sleep hygiene education alone is not effective, and may be harmful if it discourages patients from considering other CBT components. CBT for insomnia has been shown to be more effective than several sleep medications. Internet-based or group CBT can increase access, but effectiveness has not been proven. Brief behavioral treatment for insomnia is a shorter alternative to CBT focusing only on sleep restriction, stimulus control, and sleep hygiene.

Long-term medication is not recommended for chronic insomnia, and many short-term medications have risks of overuse. If medications are required, doxepin or nonbenzodiazepine receptor agonists (e.g., zolpidem [Ambien], zaleplon [Sonata], eszopiclone [Lunesta]) are recommended at the lowest effective dose for the shortest possible duration. Antipsychotics, benzodiazepines, antihistamines, and trazodone are not recommended in chronic insomnia because of adverse effects and limited effectiveness. Neither ramelteon (Rozerem) nor suvorexant (Belsomra) has sufficient evidence to recommend use.

Already a member/subscriber?  Log In

Subscribe

From $145
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available
Subscribe

Issue Access

$59.95
  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available

Article Only

$25.95
  • Immediate, unlimited access to just this article
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

Continue Reading

More in AFP

More in Pubmed

Copyright © 2021 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.